The Application dimension of Neurogenetic Testing segmentation distinguishes four primary use‑cases that together drive the market’s revenue composition. Diagnostic testing, accounting for roughly 45 % of total sales, enables clinicians to confirm hereditary neuro‑degenerative disorders through targeted gene panels, thereby generating the largest share of laboratory throughput and reimbursement streams. Prognostic applications, representing about 30 % of the market, focus on risk stratification and disease‑progression modeling, attracting payers seeking cost‑effective long‑term care planning. Therapeutic decision‑support testing, at an estimated 15 %, informs precision‑medicine interventions such as gene‑therapy eligibility, creating high‑margin niche services. Finally, Research usage, comprising roughly 10 %, supplies academic and biotech institutions with exploratory sequencing data, sustaining a smaller but innovation‑critical revenue stream. Collectively, these application categories define the market taxonomy and guide investment priorities across the Neurogenetic Testing landscape.